- Home
- CPT vs KRYS Comparison
CPT vs KRYS Comparison
Compare CPT & KRYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CPT | KRYS |
|---|---|---|
| Founded | 1993 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.8B | 10.3B |
| IPO Year | 1995 | 2017 |
Fundamental Metrics
Financial Performance| Metric | CPT | KRYS |
|---|---|---|
| Price | $112.97 | $365.80 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 17 | 11 |
| Target Price | $115.28 | ★ $297.60 |
| AVG Volume (30 Days) | ★ 976.7K | 330.3K |
| Earning Date | 04-30-2026 | 05-04-2026 |
| Dividend Yield | ★ 4.03% | N/A |
| EPS Growth | ★ 136.00 | 128.00 |
| EPS | 0.40 | ★ 1.83 |
| Revenue | $12,967,000.00 | ★ $389,130,000.00 |
| Revenue This Year | N/A | $38.74 |
| Revenue Next Year | $2.60 | $32.53 |
| P/E Ratio | $283.25 | ★ $202.78 |
| Revenue Growth | ★ 81.69 | 33.94 |
| 52 Week Low | $96.53 | $130.50 |
| 52 Week High | $119.81 | $382.54 |
Technical Indicators
Market Signals| Indicator | CPT | KRYS |
|---|---|---|
| Relative Strength Index (RSI) | 50.62 | 60.23 |
| Support Level | $105.41 | $253.89 |
| Resistance Level | $116.59 | $382.54 |
| Average True Range (ATR) | 1.95 | 13.26 |
| MACD | -0.36 | -1.03 |
| Stochastic Oscillator | 41.99 | 55.77 |
Price Performance
Historical ComparisonAbout CPT Camden Property Trust
Camden Property Trust is a real estate investment trust engaged in the ownership, management, development, reposition, redevelopment, acquisition, and construction of multifamily apartment communities. It owned interests in, operated, or developing nearly 175 multifamily properties comprised of nearly 59,921 apartment homes across the United States.
About KRYS Krystal Biotech Inc.
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.